September 14-15, 2021
Virtual Meeting

Conference Cochairs

Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England
Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, New York
Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Elizabeth M. Swisher, University of Washington, Seattle, Washington

Committed to supporting the ovarian cancer workforce and ovarian cancer patients, this year will mark the AACR’s fifth Biennial Special Conference on Ovarian Cancer. Worldwide, there were more than 313,000 new cases of ovarian cancer in 2020. The earlier that ovarian cancer is diagnosed, the better the prognosis; however, only 16% of cases are diagnosed at an early, localized stage. Understanding of risk factors and early detection are key in progress against this disease. Continued research in areas such as DNA damage/repair, immunology, and the tumor microenvironment will only further enhance our understanding of ovarian cancer biology and the development of better therapeutics as a result. This virtual Special Conference will address and discuss all of these important needs in ovarian cancer research and treatment with sessions focusing on epidemiology and prevention, immunology, tumor microenvironment, DNA damage, replication stress, genetics, and cancer evolution.

Major Supporter

Supporter

Verastem Oncology

Professional Educational Grants

AstraZeneca
GlaxoSmithKline
Merck
Novocure, Inc.

#AACRovca21